Choroidal Neovascularization (CNV) Secondary to Chorioretinitis

Choroidal neovascularization means that brand-new, fragile blood vessels grow out of the layer under the retina called the choroid. When the original trigger is chorioretinitis (inflammation of both the retina and the underlying choroid), the inflamed tissues become damaged, hypoxic, and leaky. Tiny breaks form in Bruch’s membrane (the thin barrier that normally keeps choroidal vessels away from the retina). Vascular-growth signals such as vascular-endothelial growth factor (VEGF) surge, and vessels push upward through the tear, forming a “neovascular membrane.” These vessels bleed and ooze fluid, creating blisters under or inside the retina, distorting vision and, without treatment, leaving a fibrous scar that permanently blurs central sight. Researchers now group this inflammation-driven form under the umbrella term inflammatory CNV (I-CNV) because its growth signals and leakage mimic age-related macular degeneration but the root cause is infection or autoimmune inflammation. EyeWiki

---

2. Types you may hear about

1. Type 1 (Occult, Sub-RPE): The membrane stays under the retinal-pigment epithelium (RPE); leakage is slow and sometimes hard to spot on routine fluorescein dye tests. EyeWiki

2. Type 2 (Classic, Sub-retinal): Vessels break fully through the RPE and sit in the sub-retinal space; leakage is brisk, often causing sudden fluid or hemorrhage. EyeWiki

3. Location-based sub-types: Macular, peripapillary (around the optic nerve), or peripheral; the macula is most common and most visually threatening. EyeWiki

4. Activity status: Active (leaking/bleeding on imaging), quiescent (a flat, silent scar).

5. Associated-inflammation label: Doctors may prefix the CNV with the specific uveitis (e.g., “PIC-CNV” for punctate inner choroidopathy).

---

3. Fifteen typical causes (each with a plain-language note)

1. Toxoplasma gondii infection – the parasite scars the retina; scars often sprout new vessels years later.

2. Tuberculous chorioretinitis – Mycobacterium tuberculosis inflames the choroid; chronic granulomas weaken Bruch’s membrane.

3. Syphilitic uveitis – Treponema pallidum causes deep retinal inflammation that can trigger CNV even after systemic treatment.

4. Viral retinitis (HSV/VZV/CMV) – acute necrotizing lesions heal with thin atrophic patches prone to vascular invasion.

5. Sarcoidosis – non-infectious granulomas choke local blood flow, raising VEGF.

6. Vogt-Koyanagi-Harada (VKH) disease – widespread autoimmune attack on melanocytes includes choroid; persistent edema promotes vessel growth.

7. Punctate inner choroidopathy (PIC) – tiny punched-out inflammatory spots in young myopic women; up to 75 % develop CNV. EyeWiki

8. Multifocal choroiditis – clusters of inflammatory lesions; roughly one-third spawn CNV.

9. Serpiginous choroiditis – snake-like chorioretinal waves leave atrophic edges that leak VEGF.

10. Presumed ocular histoplasmosis syndrome (POHS) – fungal scars from Histoplasma capsulatum are classic CNV beds. EyeWiki

11. Relentless placoid chorioretinitis – large placoid lesions; chronic activity increases risk. EyeWiki

12. Idiopathic posterior uveitis – inflammation of unknown cause can still damage the RPE–Bruch barrier.

13. Sympathetic ophthalmia – autoimmune attack after eye trauma leads to patchy choroiditis and membrane formation.

14. Ocular sarcoid-like reactions in lymphoma (“masquerade” syndromes) – malignant cells mimic uveitis, triggering neovascular signals. EyeWiki

15. Direct ocular trauma with secondary chorioretinitis – lacerations or intraocular foreign bodies introduce inflammation that eventually breeds CNV.

---

4. Ten key symptoms (what patients feel or notice)

1. Blurry central vision – straight lines look fuzzy because fluid pools in the macula.

2. Metamorphopsia – wavy or crooked appearance to letters or window blinds, a classic early clue. EyeWiki

3. Scotoma – a dark or gray spot that blocks part of reading text.

4. Micropsia/macropsia – objects seem smaller or larger than the unaffected eye sees.

5. Photopsia (flashes of light) – irritation of retinal cells by leaking fluid or active inflammation. EyeWiki

6. Color wash-out – reds and greens fade when macular cones are swollen.

7. Reduced contrast sensitivity – glossy magazine pages look dull.

8. Difficulty seeing at night – fluid and RPE stress inhibit rod function.

9. Floaters – loose inflammatory cells or tiny hemorrhages drift across vision.

10. Painless but progressive vision loss – no nerve pain fibres in the retina, so damage is silent.

---

5. Twenty diagnostic tests – grouped & explained

A. Physical-exam-based (4)

1. Best-corrected visual-acuity (Snellen or ETDRS chart): A simple eye-chart reading pinpoints subtle central-vision loss years before obvious scarring.

2. Color-vision plates (Ishihara or HRR): Detect cone-photoreceptor dysfunction from macular edema.

3. Contrast-sensitivity (Pelli-Robson chart): Sensitive for early haze or subretinal fluid that standard acuity can miss.

4. Dilated fundus examination: Using an ophthalmoscope, the clinician may spot a pale-yellow sub-retinal mound, fresh hemorrhage, or tell-tale inflammatory scars encircling the membrane. EyeWiki

B. Manual/bedside tests (4)

5. Amsler grid self-test: At home or in clinic, the patient stares at a dot on graph paper; wavy or missing squares flag active leakage.

6. Slit-lamp biomicroscopy with handheld macular lens: Magnifies the fovea ×90, letting the examiner see a fine “gray-green” CNV net.

7. Indirect ophthalmoscopy with scleral depression: Allows a broad survey for peripheral inflammatory scars that hint at old chorioretinitis.

8. Manual tonometry (Goldmann applanation): While not a CNV detector per se, raised pressure can accompany steroid therapy and must be checked at every visit.

C. Lab & pathological studies (4)

9. Toxoplasma IgG/IgM serology or PCR: Confirms congenital or acquired toxoplasmosis behind a scar.

10. Syphilis screening (VDRL/FTA-ABS or treponemal EIA): Essential before starting steroids or biologics.

11. QuantiFERON-TB Gold or T-spot: A positive result plus choroidal granulomas points to tuberculous uveitis.

12. Angiotensin-converting enzyme (ACE) & lysozyme levels: Helpful markers for systemic sarcoidosis driving the ocular inflammation.

D. Electrodiagnostic tests (4)

13. Full-field electroretinography (ERG): Measures overall retinal photoreceptor health; widespread depression suggests diffuse chorioretinal damage.

14. Multifocal ERG (mfERG): Plots dozens of small cone-responses; a “cold” dip in the central hexagons hints at macular dysfunction near the CNV.

15. Visual-evoked potential (VEP): Prolonged latency may show that the optic pathway is impaired by associated inflammatory edema.

16. Electro-oculography (EOG): A low Arden ratio confirms generalized RPE compromise that predisposes to CNV.

E. Imaging tests (4)

17. Spectral-domain optical coherence tomography (SD-OCT): Cross-sectional “optical biopsy” reveals sub-retinal fluid, pigment-epithelium detachments, and the CNV’s hyper-reflective core. EyeWiki

18. OCT Angiography (OCTA): A dye-free scan that maps actual blood flow; shows a coral-reef-shaped vascular plexus in early disease and monitors shrinkage after therapy. EyeWiki

19. Fluorescein angiography (FA): Sodium fluorescein dye leaks from the membrane, outlining classic “wheel-and-spoke” hyper-fluorescence.

20. Indocyanine-green angiography (ICGA): Near-infrared dye penetrates the RPE better than fluorescein, exposing feeder vessels even through hemorrhage; especially useful in inflammatory CNV buried under old scars. Aetna

Non‑Pharmacological Treatments

Below are 20 lifestyle, exercise, mind‑body and educational self‑management tools that can support medical care. Each paragraph starts with the intervention name for easy scanning.

1. Oculomotor focus‑flexibility drills – simple “pencil‑push‑ups” or figure‑of‑eight tracking improve accommodation and help patients use intact peripheral retina after central scarring. Purpose: train extra‑ocular muscles, reduce asthenopia. Mechanism: neuro‑plastic strengthening of oculo‑motor circuits.

2. Trataka yogic eye‑yoga – gazing steadily at a candle then closing eyes and visualising the flame calms eye strain and may boost parasympathetic tone, indirectly lowering ocular perfusion pressure.

3. Tai Chi walking – slow, rhythmic weight shifts improve systemic micro‑circulation and balance, helpful for low‑vision fall‑prevention.

4. Brisk‑but‑moderate aerobic walks (30 min, 5 days/week) – systemic exercise enhances endothelial nitric‑oxide, reducing chronic ocular inflammation.

5. Low‑impact resistance bands – strengthens postural muscles, cuts systemic insulin resistance and lowers VEGF expression triggered by hyperglycaemia.

6. Mindfulness meditation (20 min daily) – randomised trials show significant intra‑ocular‑pressure reduction and stress‑marker normalisation in eye disease patients, indicating real anti‑inflammatory benefit.PubMedScienceDirect

7. Guided breathing (slow 4‑7‑8 pattern) – vagal stimulation dampens cortisol and systemic cytokines that up‑regulate VEGF.

8. Progressive muscle relaxation before bedtime – improves sleep quality; good sleep reduces retinal oxidative stress.

9. Low‑vision rehabilitation services – occupational therapists teach magnifier use, screen readers, contrast‑enhancing lighting and orientation skills so patients stay independent despite central blind spots.macular.org

10. Environmental lighting upgrades – bright, glare‑controlled LED task lighting shrinks pupils and increases depth of field, letting remaining retina work harder while reducing squint‑induced fatigue.

11. Assistive voice‑command technology – smart‑phone voice control and audio books bypass visual tasks, lowering eye strain.BrightFocus Foundation

12. Smoking‑cessation coaching – smoking triples the risk of recurrent inflammatory CNV by increasing oxidative damage and VEGF; counselling plus nicotine‑replacement doubles quit success.

13. Anti‑inflammatory meal planning – dietitians teach high‑fruit‑and‑vegetable, low‑glycaemic menus rich in lutein, omega‑3 and zinc that mirror the AREDS2 formula.

14. UV‑blocking wrap‑around sunglasses – cut phototoxic retinal injury and slow pigment epithelium cell death.

15. Blue‑light screen filters – evening filter apps minimise circadian disruption and oxidative retinal stress.

16. Posture ergonomics – holding reading matter at 40 cm with neutral neck prevents additional ocular venous congestion.

17. Blood‑pressure self‑monitoring – systemic hypertension accelerates CNV leakage; home cuffs empower early adjustment.

18. Glycaemic tracking for diabetics – continuous glucose monitors reduce spikes that raise VEGF.

19. Peer‑support groups – sharing coping strategies lowers depression, which otherwise worsens self‑care.

20. Regular scheduled follow‑up – diarised eye‑check reminders catch recurrence early before irreversible bleeding.

---

Key Drugs

Anti‑VEGF biologics – the cornerstone

1. Ranibizumab 0.5 mg intravitreal monthly for 3 months then PRN: monoclonal antibody Fab blocking VEGF‑A; most patients gain 2–3 lines of vision; main side‑effects: transient eye pain, rare endophthalmitis.PubMedWikipedia

2. Bevacizumab 1.25 mg intravitreal monthly PRN: cost‑effective off‑label anti‑VEGF with similar outcomes; monitor for ocular inflammation.PubMed

3. Aflibercept 2 mg intravitreal q4 weeks ×3, then q8 weeks: fusion‑protein VEGF trap; longer posology than ranibizumab.Wikipedia

4. Brolucizumab 6 mg intravitreal q12 weeks after loading: small single‑chain antibody fragment allowing high molar VEGF blockade; watch for retinal vasculitis.

5. Faricimab 6 mg intravitreal q8–12 weeks: dual Ang‑2/VEGF‑A inhibitor offering vascular‑stabilising advantage.

Adjunct immuno‑modulators for underlying inflammation

6. Oral Prednisone 0.5–1 mg/kg/day tapered over 6–8 weeks: dampens active chorioretinitis flare that fuels CNV; side‑effects: hyperglycaemia, cataract.

7. Azathioprine 1–2 mg/kg/day: purine‑synthesis blocker for steroid‑sparring control in autoimmune uveitis; monitor liver enzymes.

8. Mycophenolate mofetil 500–1000 mg BID: inhibits IMP‑dehydrogenase in lymphocytes; delays recurrence.

9. Pyrimethamine 50 mg plus Sulfadiazine 1 g QID + Folinic acid (6–8 weeks) for ocular‑toxoplasmosis‑driven chorioretinitis; reduces parasite load that perpetuates VEGF stimulus.

10. Dexamethasone 0.7 mg intravitreal biodegradable implant lasting ~3 months; useful if oedema coexists and anti‑VEGF response is incomplete; monitor IOP rise.

---

Dietary Molecular Supplements

1. Lutein 10 mg + Zeaxanthin 2 mg daily – carotenoids concentrate in the macular pigment, filtering blue‑light and neutralising ROS; AREDS2 showed slower visual loss in moderate AMD.National Eye Institute

2. Omega‑3 DHA 500 mg + EPA 1000 mg daily – incorporated into photoreceptor membranes, modulates inflammatory eicosanoids; trials suggest tear and micro‑vascular benefits even if progression impact on AMD is mixed.PMCPMC

3. Vitamin C 500 mg – water‑soluble antioxidant replenishing ascorbate in aqueous humour.

4. Vitamin E 400 IU – lipid‑phase antioxidant protecting photoreceptor outer‑segment discs.

5. Zinc 80 mg (as zinc oxide) + Copper 2 mg – co‑factor for retinal antioxidant enzymes; prevents secondary copper deficiency from high‑dose zinc.

6. Resveratrol 150–200 mg – polyphenol activates SIRT1, up‑regulates Nrf2 and blocks oxidative apoptosis in RPE cells.PMC

7. Curcumin (Meriva® or BCM‑95®) 500 mg BID with pepperine – down‑regulates HIF‑1α and VEGF, inhibits retinal endothelial proliferation.PMC

8. Taurine 1000 mg BID – abundant retinal amino‑acid stabilising membranes and calcium; supplementation rescued photoreceptors in animal models.PMC

9. Bilberry anthocyanins 160 mg daily – improve night‑vision and capillary stability by inhibiting matrix‑metalloproteinases.

10. Alpha‑lipoic acid 300 mg daily – regenerates vitamin C and E, chelates metals, reduces oxidative lipid peroxidation in RPE.

---

Regenerative or Stem‑Cell–Based Therapies (research/early‑access)

1. OpRegen® human embryonic stem‑cell–derived RPE suspension (50–200 k cells sub‑retinal once): ongoing phase 1/2a trial reports layered RPE integration and drusen clearance, with mild immune rejection risk.ClinicalTrials.govPMC

2. iPSC‑derived RPE patch strip transplantation: allogeneic iPSC‑RPE sheets implanted under macula restored photoreceptor support in early human study.ophthalmologyscience.org

3. CNTF encapsulated‑cell implant (ENCELTO™ NT‑501): rice‑grain‑sized capsule secreting ciliary‑neurotrophic factor for two years; FDA approved 2025 for macular telangiectasia, explored in GA and inflammatory CNV; slows photoreceptor loss.Foundation Fighting BlindnessPubMed

4. RGTA® (ReGeneraTing Agent) polysaccharide eye drops (OTR4120) – mimic heparan‑sulfate to rebuild extracellular matrix, facilitating RPE repair; compassionate‑use reports show resolution of chronic leaks.

5. Gene‑edited VEGF‑silencing RNA nanoparticles (single sub‑retinal injection): pre‑clinical; CRISPR interference knocks‑down VEGF‑A to suppress angiogenesis.

6. Photobiomodulation with 670 nm low‑level‑light therapy: stimulates mitochondrial cytochrome‑c‑oxidase, enhancing RPE ATP and reducing drusen volume; early pilot studies promising.

Note: These modalities remain experimental; availability is limited to clinical‑trial centres.

---

Surgical or Procedural Options

1. Photodynamic therapy (PDT) with verteporfin: a light‑activated dye is injected IV and laser‑excited over CNV to occlude vessels while sparing retina; decades of evidence show safety in inflammatory CNV.PMCPubMed

2. Combination PDT + anti‑VEGF “sandwich” approach: PDT shrinks mature vessels; anti‑VEGF prevents rebound angiogenesis – useful for large, fibrotic CNV.PubMed

3. Pars‑plana vitrectomy with sub‑macular CNV membrane removal: in select young patients, surgical excision can gain ≥3 lines of vision when membrane is recent and small.PMCPubMed

4. Macular translocation micro‑surgery: rotates the retina onto healthier RPE/choroid when scarring is extensive; high skill, risk of torsional diplopia.

5. Sub‑threshold 577 nm micropulse laser photocoagulation: delivers “heat‑shock” cytokine modulation without visible burn, stabilising PED and micro‑leaks in para‑foveal CNV.

---

Practical Prevention Tips

1. Keep systemic inflammation low with plant‑rich, low‑glycaemic eating.

2. Control blood pressure <130/80 mm Hg.

3. Maintain HbA1c <7 % in diabetes.

4. Wear UV‑protective sunglasses outdoors.

5. Quit smoking and avoid second‑hand smoke.

6. Schedule dilated eye examinations every 3–6 months.

7. Use home Amsler‑grid weekly; report new distortion immediately.

8. Take evidence‑based AREDS2 vitamins if your ophthalmologist recommends.

9. Limit excessive screen time and apply blue‑light filters.

10. Engage in regular moderate exercise to boost micro‑circulation.

---

When to See a Doctor

Seek ophthalmic care immediately if you notice any of the following: sudden wavy or missing spots in central vision, a drop in reading clarity, new dark patch, eye pain after injection, flashing lights, or increased floaters. Early anti‑VEGF within days often preserves acuity.

---

“Do & Avoid” Guidelines

• Do eat leafy‑greens daily – Avoid ultra‑processed, high‑salt snacks.

• Do walk briskly 30 min most days – Avoid heavy lifting right after intravitreal injections.

• Do keep your injection calendar – Avoid skipping follow‑up even if vision feels fine.

• Do practise mindfulness or gentle yoga – Avoid chronic stress and sleep deprivation.

• Do protect eyes from UV – Avoid tanning beds.

• Do hydrate well – Avoid excessive alcohol which dehydrates ocular tissues.

• Do use bright task lighting – Avoid reading in dim light that forces retinal metabolic overdrive.

• Do orient your phone to dark‑mode high‑contrast – Avoid prolonged small‑font reading.

• Do update glasses annually – Avoid outdated scripts that cause squinting.

• Do join a low‑vision support group – Avoid social isolation that can trigger depression and non‑adherence.

---

Frequently Asked Questions (FAQs)

1. Is CNV after chorioretinitis curable? Early anti‑VEGF often stabilises or improves sight, but scarring cannot be reversed; ongoing monitoring is vital.

2. How many injections will I need? Typical course is monthly for three months, then as‑needed; some patients need few, others long‑term maintenance.

3. Do anti‑VEGF shots hurt? A quick anaesthetic drop and eyelid speculum make the poke mostly pressure‑not‑pain; the whole visit is under 15 minutes.

4. Can supplements replace injections? No – vitamins support retinal health but cannot shrink active neovascular vessels.

5. Is PDT still used since anti‑VEGF exists? Yes, as an adjunct for stubborn or large lesions.

6. Will stem‑cell therapy be available soon? An FDA‑approved CNTF implant is already here for macular telangiectasia; RPE transplant trials are advancing quickly.

7. Can I fly after an injection? Yes – cabin pressure changes are safe; just use artificial tears on long flights.

8. Are both eyes at risk? In inflammatory CNV, the fellow eye risk is lower than AMD but increases if underlying uveitis is uncontrolled.

9. Is it safe to exercise after injections? Light activity the same day is fine; avoid vigorous inversion positions for 24 h.

10. Can pregnancy continue anti‑VEGF therapy? Generally avoided; alternative strategies like PDT or steroids may be considered – discuss family‑planning early.

11. Will blue‑light glasses help? They reduce retinal oxidative stress at night; they are supportive, not therapeutic.

12. Does screen time worsen CNV? Not directly, but prolonged near‑focus causes dryness and asthenopia; the 20‑20‑20 rule (look 20 ft away for 20 s every 20 min) helps.

13. Can diet really change eye disease? The AREDS studies prove targeted nutrients slow macular degeneration; similar antioxidants are logical for inflammatory CNV.

14. What if injections stop working? Switching anti‑VEGF class, combination PDT, steroids, or surgery are next‑line options.

15. Will I go blind? Prompt, sustained therapy plus healthy habits usually preserves functional vision; total blindness is uncommon when care is consistent.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: July 16, 2025.

PDF Document For This Disease Conditions References